Open Access. Powered by Scholars. Published by Universities.®
Social and Behavioral Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Social and Behavioral Sciences
Immune Responses Of A Liposome/Iscom Vaccine Adjuvant Against Streptococcal Fibronectin Binding Protein 1 (Sfb1) In Mice, Jason D. Mcarthur, K Schulze, James Chin, B J. Currie, K S. Sriprakash, S R. Talay, G S. Chhatwal, C A. Guzman, Mark J. Walker
Immune Responses Of A Liposome/Iscom Vaccine Adjuvant Against Streptococcal Fibronectin Binding Protein 1 (Sfb1) In Mice, Jason D. Mcarthur, K Schulze, James Chin, B J. Currie, K S. Sriprakash, S R. Talay, G S. Chhatwal, C A. Guzman, Mark J. Walker
Faculty of Science, Medicine and Health - Papers: part A
BACKGROUND & OBJECTIVES: The fibronectin binding protein Sfb1 of Streptococcus pyogenes is a well characterised antigen which induces protection against lethal challenge with group A streptococcus (GAS) when adjuvanted with cholera toxin B-subunit (CTB). As an alternative to CTB adjuvanted intranasal immunisations we investigated the immune responses generated in mice using Sfb1 incorporated in to the skin and mucosal adjuvant SAMA4. METHODS: Mice (BALB/c) were vaccinated intradermally with 100 microl of either SAMA4 (adjuvant only group) or SAMA4/Sfb1 and were boosted 7 days later. Mice vaccinated with CTB based vaccines were immunised by intranasal inoculation with a mixture containing 30 …
Oxaliplatin, Fluorouracil, And Leucovorin As Adjuvant Treatment For Colon Cancer, Thierry Andre, Corrado Boni, Lamia Mounedji-Boudiaf, Matilde Navarro, Josep Tabernero, Tamas Hickish, Clare Topham, Marta Zaninelli, Phillip Clingan, John Bridgewater, Isabelle Tabah-Fisch, Aimery De Gramont
Oxaliplatin, Fluorouracil, And Leucovorin As Adjuvant Treatment For Colon Cancer, Thierry Andre, Corrado Boni, Lamia Mounedji-Boudiaf, Matilde Navarro, Josep Tabernero, Tamas Hickish, Clare Topham, Marta Zaninelli, Phillip Clingan, John Bridgewater, Isabelle Tabah-Fisch, Aimery De Gramont
Faculty of Science, Medicine and Health - Papers: part A
BACKGROUND: The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. METHODS: We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxatiplatin for six months. The primary end point was disease-free survival. RESULTS: A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group …